• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Galapagos NV

    4/29/25 4:44:24 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    6-K 1 d902752d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    For the month of April 2025.

    Commission File Number: 001-37384

     

     

    GALAPAGOS NV

    (Translation of registrant’s name into English)

     

     

    Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐

     

     
     


    Annual Shareholders’ Meeting and Extraordinary Shareholders’ Meeting Results

    On April 29, 2025, Galapagos NV (the “Company”) held its Annual Shareholders’ Meeting (the “Annual Meeting”). The minutes and other documentation pertaining to the Annual Meeting can be viewed at https://www.glpg.com/shareholders-meetings within 15 days of the Annual Meeting. The final results of each of the agenda items submitted to a vote of the shareholders at the Annual Meeting are set forth below.

    Annual Meeting Results

    Agenda item 2: acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2024, and approval of the allocation of the annual result as proposed by the Board of Directors

    The Company’s shareholders’ meeting resolved to approve the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2024, and the allocation of the annual result as proposed by the Board of Directors.

    Agenda item 5: acknowledgement and approval of the remuneration report

    The Company’s shareholders’ meeting resolved to approve the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2024.

    Agenda item 6: release from liability to be granted to the (current and former) members of the Board of Directors, and the statutory auditor for the performance of their respective mandates during the financial year ended on 31 December 2024.

    The Company’s shareholders’ meeting resolved, by a separate vote, to release each (current and former) member of the Board of Directors, and the statutory auditor from any liability arising from the performance of their respective mandates during the financial year ended 31 December 2024.

    Agenda item 7: appointment of Mr. Oleg Nodelman as non-executive director

    The Company’s shareholders’ meeting resolved, upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Company’s Nomination Committee, (a) to confirm the appointment by co-optation on October 6, 2024, and with effect as per October 7, 2024, following the resignation of Mr. Daniel Baker on October 6, 2024, and to appoint Mr. Oleg Nodelman as a non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders’ meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028. The shareholders’ meeting also resolved that the mandate of Mr. Oleg Nodelman will not be remunerated.

    Agenda item 8: confirmation and appointment of the statutory auditor with respect to the “assurance” of the CSRD sustainability reporting.

    The Company’s shareholders’ meeting resolved, upon proposal of the Board of Directors, in accordance with the recommendation and advice of the Company’s Audit Committee, and taking into account that the Corporate Sustainability Reporting Directive 2022/2464/EU (“CSRD”) in the meantime has been transposed into Belgian law, (a) as far as needed and required, to confirm and ratify the decision by the annual general shareholders’ meeting, which prior to the aforementioned transposition of the CSRD took place on April 30, 2024, to charge the Company’s statutory auditor, being BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Enterprise Database (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts, for a period of one year, with the assurance of the sustainability reporting of the Company, as referred to in the CSRD, for the financial year ending on December 31, 2024 in accordance with applicable law, (b) taking into account the aforementioned transposition of the CSRD that in the meantime has taken place, to extend the aforementioned mandate of BDO Bedrijfsrevisoren BV for the assurance of the sustainability reporting of the Company, as referred to in articles 3:6/1 - 3:6/8 and articles 3:32/1 - 3:32/6 of the Belgian Companies and Associations Code for a period of one year, to include also the assurance of the sustainability reporting of the Company for the financial year ending on December 31, 2025, so that (taking into account the provisions of article 3:61, §8 of the Belgian Companies and Associations Code) the first term of the statutory mandate of the statutory auditor for the assurance of the sustainability reporting of the Company in accordance with applicable law is aligned with the current mandate of the statutory auditor to audit the Company’s annual financial statement (which shall expire immediately after the annual shareholders’ meeting to be held in 2026), and (c) to determine the remuneration of BDO Bedrijfsrevisoren BV for the assurance of the Company’s sustainability reporting for the financial year ending on December 31, 2025 at EUR 80,000.00 (if any, VAT exclusive). The appointment of the statutory auditor with respect to the aforementioned assurance will expire immediately after the annual shareholders’ meeting to be held in 2026.

    The information contained in this Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, and 333-283361).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

         

    GALAPAGOS NV

          (Registrant)
    Date: April 29, 2025      

    /s/ Annelies Denecker

          Annelies Denecker
          Company Secretary
    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    8/24/2023Buy → Neutral
    Citigroup
    5/5/2023Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GLPG
    SEC Filings

    See more
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      6/25/25 6:00:10 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      6/20/25 4:10:04 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      5/28/25 6:35:28 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galapagos NV downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

      2/14/25 8:06:36 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos NV downgraded by Kepler

      Kepler downgraded Galapagos NV from Hold to Reduce

      11/20/24 7:41:53 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Galapagos NV with a new price target

      Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00

      9/9/24 7:50:07 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Appoints Aaron Cox as Chief Financial Officer

      Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership  Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025. Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth transition of responsibilities.Aaron brings more than two decades of leadership experience across biotechnology, capital markets, and M&A/corporate development. Most recently, he served as Executive Vice President an

      6/23/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

      Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG5101 demonstrated promising efficacy with durable CAR-T cell persistence and a favorable safety profile, including a 97% complete response rate, 100% MRD negativity in evaluable patients, sustained CAR-T expansion up to 21 months, and low rates of severe CRS and ICANS, with no deaths reported Mechelen, Belgium; June 18, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today presented new data from the ongoing ATALANTA-1 Phase 1/2 study of its investigational CD19 CAR T-cell therapy, GLPG

      6/18/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

      Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cells, with 89% receiving treatment within 7 days, avoiding the need for cryopreservation and cytotoxic bridging therapy Mechelen, Belgium; June 12, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) will present new data from the ongoing ATALANTA-1 Phase 1/2

      6/12/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care